AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06634108
Drug: Genistein
RxNorm normalized name: Genistein
DrugBank: Genistein (DB01645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
Trial: NCT05613296
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
Trial: NCT06423443
Drug: TAU
RxNorm normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual
Trial: NCT05006768
Drug: Olumiant (first dose)
RxNorm normalized name: Olumiant
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet contains 4 mg Barcitinib
Trial: NCT05006768
Drug: Olumiant (second dose)
RxNorm normalized name: Olumiant
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet contains 4 mg Barcitinib
Trial: NCT00000693
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000693
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05149170
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
Trial: NCT05488860
Drug: Triamcinolone acetonide(scar)/5-ALA(others)
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For scar, the drug is triamcinolone acetonide.
Trial: NCT06174987
Drug: T-DXd
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
Trial: NCT06586606
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04934410
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of etomidate during induction as decided by attending anesthesiologist
Trial: NCT04934410
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of midazolam during induction as decided by attending anesthesiologist
Trial: NCT04934410
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of sevoflurane during induction as decided by attending anesthesiologist
Trial: NCT05136963
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 milliliter of iohexol will be administrated.
Trial: NCT04271332
Drug: Arbaclofen
RxNorm normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen tablet
Trial: NCT04928261
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
Trial: NCT06632470
Drug: Vitamin B12 Injection
RxNorm normalized name: vitamin B12 Injectable Solution
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
Trial: NCT05136625
Drug: Sphenopalatine ganglion block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
Trial: NCT00212173
Drug: Sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06126991
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cetirizine at 10mg once daily will be used.
Trial: NCT06075225
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
Trial: NCT05674474
Drug: Vorasidenib
RxNorm normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as tablets.
Trial: NCT06417411
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily use of low dose aspirin.
Trial: NCT06427551
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
Trial: NCT05658458
Drug: Vericiguat (Verquvo, BAY1021189)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
Trial: NCT01222650
Drug: Silodosin
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04732624
Drug: Oral Rehydration Solution
RxNorm normalized name: terpin hydrate Oral Solution
DrugBank: Terpin hydrate (DB13163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
Trial: NCT06222944
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib: 12mg PO, QD, D1-14, Q3W;
Trial: NCT06222944
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125mg/m2 IV D1,8，Q3W
Trial: NCT04732624
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care Intravenous Fluid resuscitation
Trial: NCT04221880
Drug: Bupivacaine Hcl 0.25% Inj
RxNorm normalized name: BUPIVACAINE HCL 0.25% INJ
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine
Trial: NCT04221880
Drug: Saline Solution for Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided erector spinae plane block with 20 ml saline
Trial: NCT04221880
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
Trial: NCT04677439
Drug: Flumatinib
RxNorm normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of Flumatinib orally daily for 24 months
Trial: NCT05325775
Drug: ACER-801 50 mg BID
RxNorm normalized name: Acer Saccharum Pollen
DrugBank: Acer saccharum pollen (DB10369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BID (twice daily)
Trial: NCT05325775
Drug: ACER-801 100 mg BID
RxNorm normalized name: Acer Saccharum Pollen
DrugBank: Acer saccharum pollen (DB10369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID (twice daily)
Trial: NCT05325775
Drug: ACER-801 200 mg BID
RxNorm normalized name: Acer Saccharum Pollen
DrugBank: Acer saccharum pollen (DB10369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BID (twice daily)
Trial: NCT06519591
Drug: Cadonilimab, LM-302, S-1, paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
Trial: NCT06217120
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg daily
Trial: NCT04674566
Drug: COR-101
RxNorm normalized name: Aspi-Cor
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) single dose
Trial: NCT05330377
Drug: Gilteritinib 40 MG Oral Tablet
RxNorm normalized name: Gilteritinib 40 MG Oral Tablet
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
Trial: NCT05330377
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
Trial: NCT05330377
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
Trial: NCT05330377
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
Trial: NCT05330377
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
Trial: NCT05312112
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Observational study of venetoclax in AML
Trial: NCT05312112
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Observational study of gilteritinib in AML
Trial: NCT06211790
Drug: Anlotinib, Everolimus and Tislelizumab
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
Trial: NCT05383703
Drug: Treatment of MNC-168 enteric-coated capsules as a single oral drug
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
Trial: NCT06111625
Drug: blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
Trial: NCT05994183
Drug: Dexamethasone Oral
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
Trial: NCT06359106
Drug: 80% Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
Trial: NCT06359106
Drug: 40% Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
Trial: NCT05708391
Drug: Realgar-Indigo Naturalis Formulation
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight
Trial: NCT00000655
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000655
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05202145
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule.
Trial: NCT05202145
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule.
Trial: NCT05202145
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT05017155
Drug: Mexiletine
RxNorm normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
Trial: NCT05017155
Drug: Lamotrigine 25Mg Oral Tablet, Extended Release
RxNorm normalized name: Lamotrigine 25mg Oral tablet, extended release
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
Trial: NCT04709835
Drug: AT-527
RxNorm normalized name: AT-527
DrugBank: AT-527 (DB16451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
Trial: NCT05206539
Drug: Self-assembling peptide (P11-4)
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions.
Trial: NCT05206539
Drug: CPP-ACFP
RxNorm normalized name: CPPD
DrugBank: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine (DB14196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions
Trial: NCT05206539
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
Trial: NCT05389696
Drug: MIT-001 20mg and 40mg_Multiple administration
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple subcutaneous administration for 7 days and then blood collection
Trial: NCT06145074
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT01000714
Drug: Psirelax
RxNorm normalized name: PureLax
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04674527
Drug: Elemene
RxNorm normalized name: (-)-B-elemene
DrugBank: (-)-beta-Elemene (DB18097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
Trial: NCT04674527
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
Trial: NCT04808453
Drug: CPI-300
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
Trial: NCT04822064
Drug: Intranasal dexmedetomidine and ketamine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
Trial: NCT06216340
Drug: Henagliflozin
RxNorm normalized name: Henagliflozin
DrugBank: Henagliflozin (DB11939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg of Henagliflozin and diet-exercise therapy
Trial: NCT04894188
Drug: Goserelin 3.6 MG
RxNorm normalized name: goserelin 3.6 MG
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gosereline 3.6mg sc injection at week 1, week 5, and week 9
Trial: NCT04822064
Drug: Oral chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
Trial: NCT05778825
Drug: Oral Minoxidil
RxNorm normalized name: minoxidil Oral Tablet
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
Trial: NCT00002265
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05752409
Drug: The median dose of esketamine
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
Trial: NCT05752409
Drug: The high dose of esketamine
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.